Telix Securities Class Action Draws Flurry of Investor Notices Ahead of Lead-Plaintiff Deadline

Plaintiffs attribute investor losses to SEC and FDA disclosures revealing alleged misstatements.

Overview

Investors have until January 9, 2026 to move for appointment as lead plaintiff in the federal case covering purchases from February 21 through August 28, 2025.
Complaints claim Telix overstated progress on prostate cancer therapeutic candidates and overstated the quality of its supply chain and partners.
On July 22, 2025, Telix disclosed receipt of an SEC subpoena seeking documents on its prostate cancer disclosures, and the ADS price fell more than 13% over two trading sessions, according to the filings.
On August 28, 2025, Telix reported an FDA Complete Response Letter for TLX250-CDx citing Chemistry, Manufacturing, and Controls deficiencies and Form 483s to two third‑party partners, and the ADS price fell more than 21% over two sessions, the suits state.
Multiple plaintiff firms, including Rosen, Howard G. Smith, Faruqi & Faruqi, Glancy Prongay & Murray, Bragar Eagel & Squire, and Levi & Korsinsky, are soliciting affected investors, and no class has been certified.